Elevated serum omentin levels correlate with tumor aggressiveness and disease progression in breast cancer patients

Read full text Summarise with VIRAT
Authors: Himanshu Raj, Priyamvada Gupta, Vibhav Gautam, Sanjeev Gupta
Cited by: 0
References: 12

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Breast cancer remains the most frequently diagnosed malignancy among women globally and a leading cause of cancer related mortality. Despite significant progress in diagnosis and treatment, the disease's heterogeneity continues to challenge effective management. Recent studies suggest that metabolic dysfunction and obesity related factors contribute significantly to breast cancer risk and progression. Among various adipokines secreted by adipose tissue, omentin has emerged as a novel molecule of interest due to its insulin sensitizing and anti-inflammatory properties. This study explores the clinical relevance of serum omentin levels in breast cancer patients by comparing them with healthy controls and examining their correlation with different tumor characteristics. Serum omentin levels were significantly higher in breast cancer patients compared to those with benign breast conditions, which in turn were higher than in healthy controls. The study demonstrated a meaningful association between serum omentin levels and key clinicopathological parameters such as age, BMI, tumor size, lymph node status, tumor grade, and hormone receptor expression, reflecting its possible role in indicating disease severity and tumor biology. The findings may enhance our understanding of the metabolic tumor interface and support the potential of omentin as a diagnostic or prognostic biomarker.

Fields of Study & Subjects

Adipokines Inflammation and Metabolic Diseases Cancer Risks and Factors Breast Cancer Treatment Studies

Publication details

Journal / source
Frontiers in Oncology
Volume
16
Pages
1774692–1774692
Publication date
30 March 2026
Language
EN